R302
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 81
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- HYPOXIA+0.350
- TGF_BETA_SIGNALING+0.350
- COAGULATION+0.330
- WNT_BETA_CATENIN_SIGNALING+0.290
- NOTCH_SIGNALING+0.260
- MYC_TARGETS_V2+0.220
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.210
- MYOGENESIS+0.190
- TNFA_SIGNALING_VIA_NFKB+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.450
- E2F_TARGETS-0.410
- IL6_JAK_STAT3_SIGNALING-0.360
- G2M_CHECKPOINT-0.350
- ALLOGRAFT_REJECTION-0.270
- CHOLESTEROL_HOMEOSTASIS-0.190
- ANDROGEN_RESPONSE-0.180
- PANCREAS_BETA_CELLS-0.180
- PI3K_AKT_MTOR_SIGNALING-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R314 | — | — | 0.804 |
| 2 | SRR11296891 | — | — | 0.799 |
| 3 | ERR2208959 | — | — | 0.782 |
| 4 | X9d79253b.8c45.4bde.a42d.c399fb107400 | — | cohortMD2 | 0.754 |
| 5 | GSM5359429 | — | — | 0.747 |
| 6 | SRR975596 | — | — | 0.747 |
| 7 | SNU182_LIVER | HCC | — | 0.720 |
| 8 | 3843de1d-0eaa-48af-be58-903fcf2e5f89 | — | — | 0.712 |
| 9 | 0d373d8e-2507-4d88-8e19-d3f7b66955b4 | — | — | 0.710 |
| 10 | TCGA-CV-7421-01A-11R-2081-07 | — | — | 0.707 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.050 | Inavolisib | — uncovered |